Table of Contents Author Guidelines Submit a Manuscript
Parkinson’s Disease
Volume 2017 (2017), Article ID 3256542, 18 pages
https://doi.org/10.1155/2017/3256542
Review Article

Management of Psychosis in Parkinson’s Disease: Emphasizing Clinical Subtypes and Pathophysiological Mechanisms of the Condition

Maurice Wohl Clinical Neuroscience Institute and NIHR Biomedical Research Centre, Institute of Psychiatry, Psychology and Neuroscience, King’s College Hospital, London, UK

Correspondence should be addressed to Raquel N. Taddei; moc.liamtoh@ieddatleuqar

Received 26 May 2017; Accepted 6 August 2017; Published 12 September 2017

Academic Editor: Giovanni Mirabella

Copyright © 2017 Raquel N. Taddei et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. G. Goldman and S. Holden, “Treatment of psychosis and dementia in Parkinson's disease,” Current Treatment Options in Neurology, vol. 16, no. 3, article 281, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. W.-M. Liu, R.-J. Lin, R.-L. Yu, C.-H. Tai, C.-H. Lin, and R.-M. Wu, “The impact of nonmotor symptoms on quality of life in patients with parkinson’s disease in Taiwan,” Neuropsychiatric Disease and Treatment, vol. 11, pp. 2865–2873, 2015. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Levin, A. Hasan, and G. U. Höglinger, “Psychosis in Parkinson’s disease: identification, prevention and treatment,” Journal of Neural Transmission, vol. 123, no. 1, pp. 45–50, 2016. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Sauerbier, P. Jenner, A. Todorova, and K. R. Chaudhuri, “Non motor subtypes and Parkinson's disease,” Parkinsonism and Related Disorders, vol. 22, pp. S41–S46, 2016. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Souqes, Rapport sur les syndromes parkinsoniens. Revue neurologique, Masson, Paris, France, 1921.
  6. J. De Ajuriaguerra, Ajuriaguerra, Etude psychopathologique des parkinsoniens in Monoamines, noyaux gris centraux et syndromes parkinsoniens, Masson, Paris, France, 1971.
  7. M. Onofrj, D. Carrozzino, A. D'Amico et al., “Psychosis in parkinsonism: an unorthodox approach,” Neuropsychiatric Disease and Treatment, vol. Volume 13, pp. 1313–1330, 2017. View at Publisher · View at Google Scholar
  8. J. A. Vilensky, S. Gilman, and S. McCall, “Does the historical literature on encephalitis lethargica support a simple (direct) relationship with postencephalitic Parkinsonism?” Movement Disorders, vol. 25, no. 9, pp. 1124–1130, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. S. A. Factor, E. S. Molho, G. D. Podskalny, and D. Brown, “Parkinson's disease: drug-induced psychiatric states,” Advances in Neurology, vol. 65, pp. 115–138, 1995. View at Google Scholar · View at Scopus
  10. K. A. Josephs, “Capgras syndrome and its relationship to neurodegenerative disease,” Archives of Neurology, vol. 64, no. 12, pp. 1762–1766, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. S. A. Factor and E. S. Molho, “Threatening auditory hallucinations and cotard syndrome in Parkinson disease,” Clinical Neuropharmacology, vol. 27, no. 5, pp. 205–207, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. N. Moschopoulos, S. Kaprinis, and J. Nimatoudis, “Cotard’s syndrome: case report and a brief review of literature,” Psychiatriki, vol. 27, no. 4, pp. 296–302, 2016. View at Publisher · View at Google Scholar
  13. M. Poletti, G. Perugi, C. Logi et al., “Dopamine agonists and delusional jealousy in Parkinson's disease: A cross-sectional prevalence study,” Movement Disorders, vol. 27, no. 13, pp. 1679–1682, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. D. Georgiev, A. Danieli, L. Ocepek et al., “Othello syndrome in patients with parkinson's disease,” Psychiatria Danubina, vol. 22, no. 1, pp. 94–98, 2010. View at Google Scholar · View at Scopus
  15. World Health Organization, “The ICD-10 Classification of Mental and Behavioural Disorders,” http://www.who.int/classifications/icd/en/GRNBOOK.pdf, 1993.
  16. J. MacK, P. Rabins, K. Anderson et al., “Prevalence of psychotic symptoms in a community-based parkinson disease sample,” American Journal of Geriatric Psychiatry, vol. 20, no. 2, pp. 123–132, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. J. H. Friedman, “Parkinson disease psychosis: update,” Behavioural Neurology, vol. 27, no. 4, pp. 469–477, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. D. H. Ffytche, B. Creese, M. Politis et al., “The psychosis spectrum in Parkinson disease,” Nature Reviews Neurology, vol. 13, no. 2, pp. 81–95, 2017. View at Publisher · View at Google Scholar · View at Scopus
  19. D. H. Ffytche, J. B. Pereira, C. Ballard, K. R. Chaudhuri, D. Weintraub, and D. Aarsland, “Risk factors for early psychosis in PD: Insights from the Parkinson's Progression markers initiative,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 88, no. 4, pp. 325–331, 2017. View at Publisher · View at Google Scholar · View at Scopus
  20. B. R. Thanvi, T. C. N. Lo, and D. P. Harsh, “Psychosis in Parkinson's disease,” Postgraduate Medical Journal, vol. 81, no. 960, pp. 644–646, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Chaudhury, “Hallucinations: clinical aspects and management,” Industrial Psychiatry Journal, vol. 19, no. 1, p. 5, 2010. View at Publisher · View at Google Scholar
  22. B. Ravina, K. Marder, H. H. Fernandez et al., “Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH Work Group,” Movement Disorders, vol. 22, no. 8, pp. 1061–1068, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. G. Fenelon, “Psychosis in parkinson's disease: phenomenology, frequency, risk factors, and current understanding of pathophysiologic mechanisms,” CNS Spectrums, vol. 13, no. 3, pp. 18–25, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. J. L. Cummings, “Behavioral complications of drug treatment of Parkinson's disease,” Journal of the American Geriatrics Society, vol. 39, no. 7, pp. 708–716, 1991. View at Publisher · View at Google Scholar · View at Scopus
  25. D. Weintraub and H. I. Hurtig, “Presentation and management of psychosis in Parkinson's disease and dementia with lewy bodies,” American Journal of Psychiatry, vol. 164, no. 10, pp. 1491–1498, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. E. B. Forsaa, J. P. Larsen, T. Wentzel-Larsen et al., “A 12-year population-based study of psychosis in Parkinson disease,” Archives of Neurology, vol. 67, no. 8, pp. 996–1001, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. G. Fenelon, F. Mahieux, R. Huon, and M. Ziegler, “Hallucinations in Parkinson's disease. prevalence, phenomenology and risk factors,” Brain, American Journal of Ophthalmology, vol. 130, no. 2, pp. 261-262, 2000. View at Google Scholar
  28. C. Pacchetti, R. Manni, R. Zangaglia et al., “Relationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinson's disease,” Movement Disorders, vol. 20, no. 11, pp. 1439–1448, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. D. R. Williams, J. D. Warren, and A. J. Lees, “Using the presence of visual hallucinations to differentiate Parkinson's disease from atypical parkinsonism,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 79, no. 6, pp. 652–655, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. G. Fenelon, T. Soulas, F. Zenasni, and L. C. de Langavant, “The changing face of Parkinson's disease-associated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria,” Movement Disorders : Official Journal of The Movement Disorder Society, vol. 25, no. 6, pp. 755–759, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. S. Papapetropoulos and D. C. Mash, “Psychotic symptoms in Parkinson's disease. From description to etiology,” Journal of Neurology, vol. 252, no. 7, pp. 753–764, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. S. A. Factor, P. J. Feustel, and J. H. Friedman, “Longitudinal outcome of Parkinson's disease patients with psychosis,” Neurology, vol. 60, no. 11, pp. 1756–1761, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Lenka, S. Hegde, K. R. Jhunjhunwala, and P. K. Pal, “Interactions of visual hallucinations, rapid eye movement sleep behavior disorder and cognitive impairment in Parkinson's disease: A review,” Parkinsonism and Related Disorders, vol. 22, pp. 1–8, 2016. View at Publisher · View at Google Scholar · View at Scopus
  34. D. H. Hepp, C. C. da Hora, T. Koene et al., “Cognitive correlates of visual hallucinations in non-demented Parkinson's disease patients,” Parkinsonism and Related Disorders, vol. 19, no. 9, pp. 795–799, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. G. Fenelon, “Psychotic symptoms in Parkinson's disease,” in Psychologie & Neuropsychiatrie Du Vieillissement, pp. S17–S24, 2006. View at Google Scholar
  36. K. R. Chaudhuri, P. Martinez-Martin, R. G. Brown et al., “The metric properties of a novel non-motor symptoms scale for Parkinson's disease: results from an international pilot study,” Movement Disorders, vol. 22, no. 13, pp. 1901–1911, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. C. G. Goetz, S. Fahn, P. Martinez-Martin et al., “Movement disorder society-sponsored revision of the unified Parkinson's disease rating scale (MDS-UPDRS): process, format, and clinimetric testing plan,” Movement Disorders, vol. 22, no. 1, pp. 41–47, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. H. Sawada, T. Oeda, K. Yamamoto et al., “Trigger medications and patient-related risk factors for Parkinson disease psychosis requiring anti-psychotic drugs: A retrospective cohort study,” BMC Neurology, vol. 13, article no. 145, 2013. View at Publisher · View at Google Scholar · View at Scopus
  39. T. Voss, D. Bahr, J. Cummings, R. Mills, B. Ravina, and H. Williams, “Performance of a shortened scale for assessment of positive symptoms for parkinson's disease psychosis,” Parkinsonism and Related Disorders, vol. 19, no. 3, pp. 295–299, 2013. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Rodriguez-Violante, A. Cervantes-Arriaga, S. Velázquez-Osuna et al., “Independent validation of the SEND-PD and correlation with the MDS-UPDRS part IA,” Parkinson's Disease, vol. 2014, Article ID 260485, 5 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  41. E. M. Kester, “Charles bonnet syndrome: case presentation and literature review,” Optometry, vol. 80, no. 7, pp. 360–366, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. B. W. Rovner, “The charles bonnet syndrome: a review of recent research,” Current Opinion in Ophthalmology, vol. 17, no. 3, pp. 275–277, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. J. C. Khan, H. Shahid, D. A. Thurlby, J. R. W. Yates, and A. T. Moore, “Charles Bonnet syndrome in age-related macular degeneration: The nature and frequency of images in subjects with end-stage disease,” Ophthalmic Epidemiology, vol. 15, no. 3, pp. 202–208, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. G. Schultz and R. Melzack, “The Charles Bonnet syndrome: 'phantom visual images'.,” Perception, vol. 20, no. 6, pp. 809–825, 1991. View at Publisher · View at Google Scholar · View at Scopus
  45. R. J. Teunisse, F. G. Zitman, and D. C. M. Raes, “Clinical evaluation of 14 patients with the Charles Bonnet syndrome (isolated visual hallucinations),” Comprehensive Psychiatry, vol. 35, no. 1, pp. 70–75, 1994. View at Publisher · View at Google Scholar · View at Scopus
  46. M. Onofrj, J. P. Taylor, D. Monaco et al., “Visual Hallucinations in PD and Lewy body dementias: old and new hypotheses,” Behavioural Neurology, vol. 27, no. 4, pp. 479–493, 2013. View at Publisher · View at Google Scholar · View at Scopus
  47. L. Pang, “Hallucinations experienced by visually impaired: Charles bonnet syndrome,” Optometry and Vision Science, vol. 93, no. 12, pp. 1466–1478, 2016. View at Publisher · View at Google Scholar · View at Scopus
  48. M. Manford and F. Andermann, “Complex visual hallucinations. Clinical and neurobiological insights,” Brain, vol. 121, no. 10, pp. 1819–1840, 1998. View at Publisher · View at Google Scholar · View at Scopus
  49. V. Biousse, B. C. Skibell, R. L. Watts, D. N. Loupe, C. Drews-Botsch, and N. J. Newman, “Ophthalmologic features of Parkinson's disease,” Neurology, vol. 62, no. 2, pp. 177–180, 2004. View at Publisher · View at Google Scholar · View at Scopus
  50. D. Aarsland, B. Creese, M. Politis et al., “Cognitive decline in Parkinson disease,” Nature Reviews Neurology, 2017. View at Publisher · View at Google Scholar · View at Scopus
  51. N. E. Fritz, D. A. Kegelmeyer, A. D. Kloos et al., “Motor performance differentiates individuals with Lewy body dementia, Parkinson's and Alzheimer's disease,” Gait and Posture, vol. 50, pp. 1–7, 2016. View at Publisher · View at Google Scholar · View at Scopus
  52. A. J. Harding, G. A. Broe, and G. M. Halliday, “Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe,” Brain, vol. 125, no. 2, pp. 391–403, 2002. View at Publisher · View at Google Scholar · View at Scopus
  53. D. A. Gallagher, L. Parkkinen, S. S. O'Sullivan et al., “Testing an aetiological model of visual hallucinations in Parkinson's disease,” Brain, vol. 134, no. 11, pp. 3299–3309, 2011. View at Publisher · View at Google Scholar · View at Scopus
  54. J. G. Goldman, G. T. Stebbins, V. Dinh et al., “Visuoperceptive region atrophy independent of cognitive status in patients with Parkinson's disease with hallucinations,” Brain, vol. 137, no. 3, pp. 849–859, 2014. View at Publisher · View at Google Scholar · View at Scopus
  55. S. Varanese, B. Perfetti, D. Monaco et al., “Fluctuating cognition and different cognitive and behavioural profiles in Parkinson's disease with dementia: Comparison of dementia with Lewy bodies and Alzheimer's disease,” Journal of Neurology, vol. 257, no. 6, pp. 1004–1011, 2010. View at Publisher · View at Google Scholar · View at Scopus
  56. A. Moser, J. Hagenah, and D. Kömpf, “Hallucinations in Parkinson's disease,” Nervenarzt, vol. 74, no. 4, pp. 376–386, 2003. View at Publisher · View at Google Scholar · View at Scopus
  57. T. Müller, H. Baas, J. Kassubek et al., “Laboratory assessments in the course of Parkinson’s disease: a clinician’s perspective,” Journal of Neural Transmission, vol. 123, no. 1, pp. 65–71, 2016. View at Publisher · View at Google Scholar · View at Scopus
  58. E. R. L. C. Vardy, A. Teodorczuk, and A. J. Yarnall, “Review of delirium in patients with Parkinson’s disease,” Journal of Neurology, vol. 262, no. 11, pp. 2401–2410, 2015. View at Publisher · View at Google Scholar · View at Scopus
  59. M. Lubomski, R. L. Rushworth, and S. Tisch, “Hospitalisation and comorbidities in Parkinson's disease: a large Australian retrospective study,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 86, no. 3, pp. 324–329, 2015. View at Publisher · View at Google Scholar · View at Scopus
  60. OH. Gerlach, MP. Broen, and WE. Weber, “Motor outcomes during hospitalization in Parkinson's disease patients: a prospective study,” Parkinsonism & related disorders, vol. 19, pp. 737–741, 2013. View at Google Scholar
  61. M. Boorsma, K. J. Joling, D. H. M. Frijters, M. E. Ribbe, G. Nijpels, and H. P. J. Van Hout, “The prevalence, incidence and risk factors for delirium in Dutch nursing homes and residential care homes,” International Journal of Geriatric Psychiatry, vol. 27, no. 7, pp. 709–715, 2012. View at Publisher · View at Google Scholar · View at Scopus
  62. J. Francis, “Diagnosis of delirium and confusional states,” 2017.
  63. L. Patti and S. Dulebohn, Change, Mental Status, StatPearls Publishing, FL, USA, 2017.
  64. M. Onofrj and A. Thomas, “Acute akinesia in Parkinson disease,” Neurology, vol. 64, no. 7, pp. 1162–1169, 2005. View at Publisher · View at Google Scholar · View at Scopus
  65. A. Thomas, D. Iacono, A. L. Luciano, K. Armellino, and M. Onofrj, “Acute akinesia or akinetic crisis in Parkinson's disease,” Neurological Sciences, vol. 24, no. 3, pp. 219-220, 2003. View at Publisher · View at Google Scholar · View at Scopus
  66. M. Simonetto, L. Ferigo, L. Zanet et al., “Acute akinesia, an unusual complication in Parkinson's Disease: A case report,” Neurological Sciences, vol. 29, no. 3, pp. 181–183, 2008. View at Publisher · View at Google Scholar · View at Scopus
  67. V. Kaasinen, J. Joutsa, T. Noponen, and M. Päivärinta, “Akinetic crisis in parkinson's disease is associated with a severe loss of striatal dopamine transporter function: A report of two cases,” Case Reports in Neurology, vol. 6, no. 3, pp. 275–280, 2014. View at Publisher · View at Google Scholar · View at Scopus
  68. M. Onofrj, L. Bonanni, G. Cossu, D. Manca, F. Stocchi, and A. Thomas, “Emergencies in parkinsonism: akinetic crisis, life-threatening dyskinesias, and polyneuropathy during L-Dopa gel treatment,” Parkinsonism and Related Disorders, vol. 15, no. 3, pp. S233–S236, 2009. View at Publisher · View at Google Scholar · View at Scopus
  69. U. Lertxundi, A. I. Ruiz, M. Á. S. Aspiazu et al., “Adverse reactions to antipsychotics in parkinson disease: An analysis of the Spanish Pharmacovigilance database,” Clinical Neuropharmacology, vol. 38, no. 3, pp. 69–84, 2015. View at Publisher · View at Google Scholar · View at Scopus
  70. A. Schattner, E. Kitroser, and J. D. Cohen, “Fatal Neuroleptic Malignant Syndrome Associated with Quetiapine,” American Journal of Therapeutics, vol. 23, no. 5, pp. e1209–e1210, 2016. View at Publisher · View at Google Scholar · View at Scopus
  71. Y. T. Kwak, Y. Yang, and M. Koo, “Late-Onset Psychosis; Is It Real?” Dementia and Neurocognitive Disorders, vol. 14, no. 1, p. 1, 2015. View at Publisher · View at Google Scholar
  72. J. Pagonabarraga, S. Martinez-Horta, R. Fernández de Bobadilla et al., “Minor hallucinations occur in drug-naive Parkinson's disease patients, even from the premotor phase,” Movement Disorders, vol. 31, no. 1, pp. 45–52, 2016. View at Publisher · View at Google Scholar · View at Scopus
  73. N. Samudra, N. Patel, K. B. Womack, P. Khemani, and S. Chitnis, “Psychosis in parkinson disease: a review of etiology, phenomenology, and management,” Drugs and Aging, vol. 33, no. 12, pp. 855–863, 2016. View at Publisher · View at Google Scholar · View at Scopus
  74. A. H. Lee and D. Weintraub, “Psychosis in Parkinson’s disease without dementia: Common and comorbid with other non-motor symptoms,” Movement Disorders, vol. 27, no. 7, pp. 858–863, 2012. View at Publisher · View at Google Scholar · View at Scopus
  75. D. A. Gallagher and A. Schrag, “Psychosis, apathy, depression and anxiety in Parkinson's disease,” Neurobiology of Disease, vol. 46, no. 3, pp. 581–589, 2012. View at Publisher · View at Google Scholar · View at Scopus
  76. E. Oikonomou and T. Paparrigopoulos, “Neuropsychiatric manifestations in Parkinson's disease,” Psychiatrike = Psychiatriki, vol. 26, no. 2, pp. 116–130, 2015. View at Google Scholar · View at Scopus
  77. C. G. Goetz, C. M. Tanner, and H. L. Klawans, “Pharmacology of hallucinations induced by long-term drug therapy,” American Journal of Psychiatry, vol. 139, no. 4, pp. 494–497, 1982. View at Publisher · View at Google Scholar · View at Scopus
  78. E. C. Wolters, “Intrinsic and extrinsic psychosis in Parkinson's disease,” Journal of Neurology, vol. 248, no. S3, pp. 22–27, 2001. View at Publisher · View at Google Scholar
  79. T. H. Svensson, J. M. Mathé, J. L. Andersson, B. G. Nomikos, B. E. Hildebrand, and M. Marcus, “Mode of action of atypical neuroleptics in relation to the phencyclidine model of schizophrenia: role of 5-HT2 receptor and α1-adrenoreceptor antagonism,” Journal of Clinical Psychopharmacology, vol. 15, pp. 11S–18S, 1995. View at Publisher · View at Google Scholar
  80. W. Birkmayer and P. Riederer, “Responsibility of extrastriatal areas for the appearance of psychotic symptoms (Clinical and biochemical human post-mortem findings),” Journal of Neural Transmission, vol. 37, no. 2, pp. 175–182, 1975. View at Publisher · View at Google Scholar · View at Scopus
  81. K. Jellinger, “Neuropathological substrates of Alzheimer's disease and Parkinson's disease.,” Journal of Neural Transmission, Supplement, vol. 24, pp. 109–129, 1987. View at Google Scholar · View at Scopus
  82. P. J. Whitehouse, J. C. Hedreen, C. L. White, and D. L. Price, “Basal forebrain neurons in the dementia of Parkinson disease,” Annals of Neurology, vol. 13, no. 3, pp. 243–248, 1983. View at Publisher · View at Google Scholar · View at Scopus
  83. E. K. Perry, E. Marshall, J. Kerwin et al., “Evidence of a Monoaminergic‐Cholinergic Imbalance Related to Visual Hallucinations in Lewy Body Dementia,” Journal of Neurochemistry, vol. 55, no. 4, pp. 1454–1456, 1990. View at Publisher · View at Google Scholar · View at Scopus
  84. E. K. Perry, I. McKeith, P. Thompson et al., “Topography, extent, and clinical relevance of neurochemical deficits in dementia of Lewy body type, Parkinson's disease, and Alzheimer's disease,” Annals of the New York Academy of Sciences, vol. 640, pp. 197–202, 1991. View at Publisher · View at Google Scholar · View at Scopus
  85. C. G. Goetz, P. F. Burke, S. Leurgans et al., “Genetic variation analysis in Parkinson disease patients with and without hallucinations: Case-control study,” Archives of Neurology, vol. 58, no. 2, pp. 209–213, 2001. View at Publisher · View at Google Scholar · View at Scopus
  86. A. J. Makoff, J. M. Graham, M. J. Arranz et al., “Association study of dopamine receptor gene polymorphisms with drug-induced hallucinations in patients with idiopathic Parkinson's disease,” Pharmacogenetics, vol. 10, no. 1, pp. 43–48, 2000. View at Publisher · View at Google Scholar · View at Scopus
  87. J. Wang, C. Zhao, B. Chen, and Z.-L. Liu, “Polymorphisms of dopamine receptor and transporter genes and hallucinations in Parkinson's disease,” Neuroscience Letters, vol. 355, no. 3, pp. 193–196, 2004. View at Publisher · View at Google Scholar · View at Scopus
  88. M. J. Frank, L. C. Seeberger, and R. C. O'Reilly, “By carrot or by stick: cognitive reinforcement learning in Parkinsonism,” Science, vol. 306, no. 5703, pp. 1940–1943, 2004. View at Publisher · View at Google Scholar · View at Scopus
  89. D. G. Harden and A. A. Grace, “Activation of dopamine cell firing by repeated L-DOPA administration to dopamine-depleted rats: Its potential role in mediating the therapeutic response to L-DOPA treatment,” Journal of Neuroscience, vol. 15, no. 9, pp. 6157–6166, 1995. View at Google Scholar · View at Scopus
  90. H. L. Klawans Jr., “The pharmacology of extrapyramidal movement disorders,” Monographs in Neural Sciences, vol. 2, pp. 1–136, 1973. View at Google Scholar · View at Scopus
  91. R. Betarbet and J. T. Greenamyre, “Regulation of dopamine receptor and neuropeptide expression in the basal ganglia of monkeys treated with MPTP,” Experimental Neurology, vol. 189, no. 2, pp. 393–403, 2004. View at Publisher · View at Google Scholar · View at Scopus
  92. J. O. Rinne, A. Laihinen, H. Ruottinen et al., “Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with [11C]raclopride,” Journal of the Neurological Sciences, vol. 132, no. 2, pp. 156–161, 1995. View at Publisher · View at Google Scholar · View at Scopus
  93. L. Rioux, P. A. Frohna, J. N. Joyce, and J. S. Schneider, “The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of Parkinsonian monkeys,” Movement Disorders, vol. 12, no. 2, pp. 148–158, 1997. View at Publisher · View at Google Scholar · View at Scopus
  94. O. D. Howes and S. Kapur, “The dopamine hypothesis of schizophrenia: version III—the final common pathway,” Schizophrenia Bulletin, vol. 35, no. 3, pp. 549–562, 2009. View at Publisher · View at Google Scholar · View at Scopus
  95. C. R. Housden, S. S. O'Sullivan, E. M. Joyce, A. J. Lees, and J. P. Roiser, “Intact reward learning but elevated delay discounting in Parkinson's disease patients with impulsive-compulsive spectrum behaviors,” Neuropsychopharmacology, vol. 35, no. 11, pp. 2155–2164, 2010. View at Publisher · View at Google Scholar · View at Scopus
  96. H. Nagy, E. Levy-Gigi, Z. Somlai, A. Takáts, D. Bereczki, and S. Kéri, “The effect of dopamine agonists on adaptive and aberrant salience in Parkinson's disease,” Neuropsychopharmacology, vol. 37, no. 4, pp. 950–958, 2012. View at Publisher · View at Google Scholar · View at Scopus
  97. C. G. Goetz, E. J. Pappert, L. M. Blasucci et al., “Intravenous levodopa in hallucinating Parkinson's disease patients: high-dose challenge does not precipitate hallucinations,” Neurology, vol. 50, no. 2, pp. 515–517, 1998. View at Publisher · View at Google Scholar · View at Scopus
  98. A. Lenka, S. Hegde, S. S. Arumugham, and P. K. Pal, “Pattern of cognitive impairment in patients with Parkinson's disease and psychosis: a critical review,” Parkinsonism and Related Disorders, vol. 37, pp. 11–18, 2017. View at Publisher · View at Google Scholar · View at Scopus
  99. S. A. Factor, W. M. McDonald, and F. C. Goldstein, “The role of neurotransmitters in the development of Parkinson's disease-related psychosis,” European Journal of Neurology. View at Publisher · View at Google Scholar
  100. A. Lenka, K. R. Jhunjhunwala, J. Saini, and P. K. Pal, “Structural and functional neuroimaging in patients with Parkinson's disease and visual hallucinations: A critical review,” Parkinsonism and Related Disorders, vol. 21, no. 7, pp. 683–691, 2015. View at Publisher · View at Google Scholar · View at Scopus
  101. A. M. Meppelink, B. M. de Jong, L. K. Teune, and T. van Laar, “Regional cortical grey matter loss in Parkinson's disease without dementia is independent from visual hallucinations,” Movement Disorders, vol. 26, no. 1, pp. 142–147, 2011. View at Publisher · View at Google Scholar · View at Scopus
  102. A. A. Kehagia, R. A. Barker, and T. W. Robbins, “Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease,” The Lancet Neurology, vol. 9, no. 12, pp. 1200–1213, 2010. View at Publisher · View at Google Scholar · View at Scopus
  103. E. K. Perry and R. H. Perry, “Acetylcholine and Hallucinations - Disease-Related Compared to Drug-Induced Alterations in Human Consciousness,” Brain and Cognition, vol. 28, no. 3, pp. 240–258, 1995. View at Publisher · View at Google Scholar · View at Scopus
  104. E. K. Perry, D. Irving, J. M. Kerwin et al., “Cholinergic transmitter and neurotrophic activities in lewy body dementia: similarity to parkinson's and distinction from alzheimer disease,” Alzheimer Disease and Associated Disorders, vol. 7, no. 2, pp. 69–79, 1993. View at Publisher · View at Google Scholar · View at Scopus
  105. I. McKeith, T. del Ser, P. Spano et al., “Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study,” The Lancet, vol. 356, no. 9247, pp. 2031–2036, 2000. View at Publisher · View at Google Scholar · View at Scopus
  106. M. Emre, D. Aarsland, A. Albanese et al., “Rivastigmine for dementia associated with Parkinson's disease,” The New England Journal of Medicine, vol. 351, no. 24, pp. 2509–2518, 2004. View at Publisher · View at Google Scholar · View at Scopus
  107. N. Stefanis, M. Bozi, C. Christodoulou et al., “Isolated delusional syndrome in Parkinson's Disease,” Parkinsonism and Related Disorders, vol. 16, no. 8, pp. 550–552, 2010. View at Publisher · View at Google Scholar · View at Scopus
  108. S. A. Factor, M. K. Scullin, A. B. Sollinger et al., “Cognitive correlates of hallucinations and delusions in Parkinson's disease,” Journal of the Neurological Sciences, vol. 347, no. 1-2, pp. 316–321, 2014. View at Publisher · View at Google Scholar · View at Scopus
  109. A. J. Atkinson Jr., W. A. Colburn, V. G. DeGruttola et al., “Biomarkers and surrogate endpoints: preferred definitions and conceptual framework,” Clinical Pharmacology and Therapeutics, vol. 69, no. 3, pp. 89–95, 2001. View at Publisher · View at Google Scholar · View at Scopus
  110. M. Gerlach, W. Maetzler, K. Broich et al., “Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics,” Journal of Neural Transmission, vol. 119, no. 1, pp. 39–52, 2012. View at Publisher · View at Google Scholar · View at Scopus
  111. K. Marek, D. Jennings, S. Lasch et al., “The parkinson progression marker initiative (PPMI),” Progress in Neurobiology, vol. 25, no. 4, pp. 629–635, 2011. View at Google Scholar
  112. R. E. Skogseth, K. Bronnick, J. B. Pereira et al., “Associations between cerebrospinal fluid biomarkers and cognition in early Untreated Parkinson's Disease,” Journal of Parkinson's Disease, vol. 5, no. 4, pp. 783–792, 2015. View at Publisher · View at Google Scholar · View at Scopus
  113. A. L. Stav, D. Aarsland, K. K. Johansen, E. Hessen, E. Auning, and T. Fladby, “Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease,” Parkinsonism and Related Disorders, vol. 21, no. 7, pp. 758–764, 2015. View at Publisher · View at Google Scholar · View at Scopus
  114. C.-H. Lin and R.-M. Wu, “Biomarkers of cognitive decline in Parkinson's disease,” Parkinsonism & Related Disorders, vol. 21, no. 5, pp. 431–443, 2015. View at Publisher · View at Google Scholar
  115. C. D. Jeffries, D. O. Perkins, S. D. Chandler et al., “Insights into psychosis risk from leukocyte microRNA expression,” Translational Psychiatry, vol. 6, no. 12, p. e981, 2016. View at Publisher · View at Google Scholar
  116. C.-Y. Lai, S.-L. Yu, and M. H. Hsieh, “MicroRNA expression aberration as potential peripheral blood biomarkers for Schizophrenia,” PLoS ONE, vol. 6, no. 6, Article ID e21635, 2011. View at Publisher · View at Google Scholar · View at Scopus
  117. E. Via, C. Orfila, C. Pedreño et al., “Structural alterations of the pyramidal pathway in schizoid and schizotypal cluster A personality disorders,” International Journal of Psychophysiology, vol. 110, pp. 163–170, 2016. View at Publisher · View at Google Scholar · View at Scopus
  118. M.-S. Koo, C. C. Dickey, H.-J. Park et al., “Smaller neocortical gray matter and larger sulcal cerebrospinal fluid volumes in neuroleptic-naive women with schizotypal personality disorder,” Archives of General Psychiatry, vol. 63, no. 10, pp. 1090–1100, 2006. View at Publisher · View at Google Scholar · View at Scopus
  119. J. Taylor, W. S. Anderson, J. Brandt, Z. Mari, and G. M. Pontone, “Neuropsychiatric complications of parkinson disease treatments: importance of multidisciplinary care,” American Journal of Geriatric Psychiatry, vol. 24, no. 12, pp. 1171–1180, 2016. View at Publisher · View at Google Scholar · View at Scopus
  120. P. D. McGorry, “Psychoeducation in first-episode psychosis: a therapeutic process,” Psychiatry (New York), vol. 58, no. 4, pp. 313–328, 1995. View at Publisher · View at Google Scholar · View at Scopus
  121. C. Pacchetti, F. Mancini, R. Aglieri, C. Fundaró, E. Martignoni, and G. Nappi, “Active music therapy in Parkinson's disease: an integrative method for motor and emotional rehabilitation,” Psychosomatic Medicine, vol. 62, no. 3, pp. 386–393, 2000. View at Publisher · View at Google Scholar · View at Scopus
  122. K. Seppi, D. Weintraub, M. Coelho et al., “The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson's disease,” Movement Disorders, vol. 26, no. 3, pp. S42–S80, 2011. View at Publisher · View at Google Scholar · View at Scopus
  123. B. S. Connolly and A. E. Lang, “Pharmacological treatment of Parkinson disease: a review,” Journal of the American Medical Association, vol. 311, no. 16, pp. 1670–1683, 2014. View at Publisher · View at Google Scholar · View at Scopus
  124. S. Grover, M. Somaiya, S. Kumar, and A. Avasthi, “Psychiatric aspects of Parkinson's disease,” Journal of Neurosciences in Rural Practice, vol. 6, no. 1, pp. 65–76, 2015. View at Publisher · View at Google Scholar · View at Scopus
  125. S. Chen, P. Chan, S. Sun et al., “The recommendations of Chinese Parkinson's disease and movement disorder society consensus on therapeutic management of Parkinson's disease,” Translational Neurodegeneration, vol. 5, no. 1, p. 12, 2016. View at Publisher · View at Google Scholar · View at Scopus
  126. S. A. Factor, J. H. Friedman, M. C. Lannon, D. Oakes, and K. Bourgeois, “Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: results of the 12 week open label extension in the PSYCLOPS trial,” Movement Disorders, vol. 16, no. 1, pp. 135–139, 2001. View at Publisher · View at Google Scholar · View at Scopus
  127. P. Pollak, F. Tison, O. Rascol et al., “Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 75, no. 5, pp. 689–695, 2004. View at Publisher · View at Google Scholar · View at Scopus
  128. D. Weintraub, C. Chiang, H. M. Kim et al., “Association of antipsychotic use with mortality risk in patients with Parkinson disease,” JAMA Neurology, vol. 73, no. 5, pp. 535–541, 2016. View at Publisher · View at Google Scholar
  129. J. L. Goren and G. M. Levin, “Quetiapine, an atypical antipsychotic,” Pharmacotherapy, vol. 18, no. 6 I, pp. 1183–1194, 1998. View at Google Scholar · View at Scopus
  130. L. Morgante, A. Epifanio, E. Spina et al., “Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis,” Clinical Neuropharmacology, vol. 27, no. 4, pp. 153–156, 2004. View at Publisher · View at Google Scholar · View at Scopus
  131. D. Merims, M. Balas, C. Peretz, H. Shabtai, and N. Giladi, “Rater-blinded, prospective comparison: quetiapine versus clozapine for parkinson's disease psychosis,” Clinical Neuropharmacology, vol. 29, no. 6, pp. 331–337, 2006. View at Publisher · View at Google Scholar · View at Scopus
  132. W. G. Ondo, R. Tintner, K. D. Voung, D. Lai, and G. Ringholz, “Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease,” Movement Disorders, vol. 20, no. 8, pp. 958–963, 2005. View at Publisher · View at Google Scholar · View at Scopus
  133. J. M. Rabey, T. Prokhorov, A. Miniovitz, E. Dobronevsky, and C. Klein, “Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration,” Movement Disorders, vol. 22, no. 3, pp. 313–318, 2007. View at Publisher · View at Google Scholar · View at Scopus
  134. P. Shotbolt, M. Samuel, C. Fox, and A. S. David, “A randomized controlled trial of quetiapine for psychosis in Parkinson's disease,” Neuropsychiatric Disease and Treatment, vol. 5, no. 1, pp. 327–332, 2009. View at Google Scholar · View at Scopus
  135. A. Breier, V. K. Sutton, P. D. Feldman et al., “Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease,” Biological Psychiatry, vol. 52, no. 5, pp. 438–445, 2002. View at Publisher · View at Google Scholar · View at Scopus
  136. W. G. Ondo, J. K. Levy, K. D. Vuong, C. Hunter, and J. Jankovic, “Olanzapine treatment for dopaminergic-induced hallucinations,” Movement Disorders, vol. 17, no. 5, pp. 1031–1035, 2002. View at Publisher · View at Google Scholar · View at Scopus
  137. H. Calderón-Fajardo, A. Cervantes-Arriaga, R. Llorens-Arenas, J. Ramírez-Bermudez, Á. Ruiz-Chow, and M. Rodríguez-Violante, “Electroconvulsive therapy in Parkinson’s disease,” Arquivos de Neuro-Psiquiatria, vol. 73, no. 10, pp. 856–860, 2015. View at Publisher · View at Google Scholar · View at Scopus
  138. G. Meco, A. Alessandri, P. Giustini, and V. Bonifati, “Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: an open-label, long-term study,” Movement Disorders, vol. 12, no. 4, pp. 610–612, 1997. View at Publisher · View at Google Scholar · View at Scopus
  139. L. Pintor, F. Valldeoriola, E. Baillés, M. J. Martí, A. Muñiz, and E. Tolosa, “Ziprasidone versus clozapine in the treatment of psychotic symptoms in Parkinson disease: a randomized open clinical trial,” Clinical Neuropharmacology, vol. 35, no. 2, pp. 61–66, 2012. View at Publisher · View at Google Scholar · View at Scopus
  140. J. H. Friedman, “Melperone is ineffective in treating Parkinson's disease psychosis,” Movement Disorders, vol. 27, no. 6, pp. 803-804, 2012. View at Publisher · View at Google Scholar · View at Scopus
  141. K. E. Vanover, D. M. Weiner, M. Makhay et al., “Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2- methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine2A receptor inverse agonist,” Journal of Pharmacology and Experimental Therapeutics, vol. 317, no. 2, pp. 910–918, 2006. View at Publisher · View at Google Scholar · View at Scopus
  142. N. S. Hunter, K. C. Anderson, and A. Cox, “Pimavanserin,” Drugs of Today, vol. 51, no. 11, pp. 646–652, 2015. View at Publisher · View at Google Scholar · View at Scopus
  143. A. Abbas and B. L. Roth, “Pimavanserin tartrate: A 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders,” Expert Opinion on Pharmacotherapy, vol. 9, no. 18, pp. 3251–3259, 2008. View at Publisher · View at Google Scholar · View at Scopus
  144. J. Cummings, S. Isaacson, R. Mills et al., “Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial,” The Lancet, vol. 383, no. 9916, pp. 533–540, 2014. View at Publisher · View at Google Scholar · View at Scopus
  145. H. Y. Meltzer, R. Mills, S. Revell et al., “Pimavanserin, a serotonin 2A receptor inverse agonist, for the treatment of Parkinson's disease psychosis,” Neuropsychopharmacology, vol. 35, no. 4, pp. 881–892, 2010. View at Publisher · View at Google Scholar · View at Scopus
  146. I. Leroi, J. Brandt, S. G. Reich et al., “Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease,” International Journal of Geriatric Psychiatry, vol. 19, no. 1, pp. 1–8, 2004. View at Publisher · View at Google Scholar · View at Scopus
  147. K. Szigeti and M. U. Hafeez, “Exploring the role of donepezil in Dementia with Lewy Bodies,” Drugs of Today, vol. 51, no. 10, pp. 579–590, 2015. View at Publisher · View at Google Scholar · View at Scopus
  148. J. Cummings, T.-J. Lai, S. Hemrungrojn et al., “Role of Donepezil in the Management of Neuropsychiatric Symptoms in Alzheimer's Disease and Dementia with Lewy Bodies,” CNS Neuroscience and Therapeutics, vol. 22, no. 3, pp. 159–166, 2016. View at Publisher · View at Google Scholar · View at Scopus
  149. H. Sawada and T. Oeda, “Protocol for a randomised controlled trial: Efficacy of donepezil against psychosis in Parkinson's disease (EDAP),” BMJ Open, vol. 3, no. 9, Article ID e003533, 2013. View at Publisher · View at Google Scholar · View at Scopus
  150. D. Popeo and C. H. Kellner, “ECT for Parkinson's disease,” Medical Hypotheses, vol. 73, no. 4, pp. 468-469, 2009. View at Publisher · View at Google Scholar · View at Scopus
  151. R. Kennedy, D. Mittal, and J. O'Jile, “Electroconvulsive Therapy in Movement Disorders: An Update,” Journal of Neuropsychiatry and Clinical Neurosciences, vol. 15, no. 4, pp. 407–421, 2003. View at Publisher · View at Google Scholar · View at Scopus
  152. P. Baldinger, A. Lotan, R. Frey, S. Kasper, B. Lerer, and R. Lanzenberger, “Neurotransmitters and electroconvulsive therapy,” Journal of ECT, vol. 30, no. 2, pp. 116–121, 2014. View at Publisher · View at Google Scholar · View at Scopus
  153. L. M. McCormick, L. L. Boles Ponto, R. K. Pierson, H. J. Johnson, V. Magnotta, and M. C. Brumm, “Metabolic correlates of antidepressant and antipsychotic response in patients with psychotic depression undergoing electroconvulsive therapy,” Journal of ECT, vol. 23, no. 4, pp. 265–273, 2007. View at Publisher · View at Google Scholar · View at Scopus
  154. F. Vila-Rodriguez, A. McGirr, J. Tham, G. Hadjipavlou, and C. R. Honey, “Electroconvulsive therapy in patients with deep brain stimulators,” Journal of ECT, vol. 30, no. 3, pp. e16–e18, 2014. View at Publisher · View at Google Scholar · View at Scopus
  155. S. Piccoli, G. Perini, S. Pizzighello et al., “A long term effects of a new onset psychosis after DBS treated with Quetiapine in a patient with Parkinson’s disease,” Psychiatry Investigation, vol. 12, no. 1, pp. 146–149, 2015. View at Publisher · View at Google Scholar · View at Scopus
  156. A. A. Qureshi, J. J. Cheng, A. N. Sunshine et al., “Postoperative symptoms of psychosis after deep brain stimulation in patients with Parkinson's disease,” Neurosurgical Focus, vol. 38, no. 6, article no. E5, 2015. View at Publisher · View at Google Scholar · View at Scopus
  157. P. Alonso, D. Cuadras, L. Gabriëls et al., “Deep brain stimulation for obsessive-compulsive disorder: a meta-analysis of treatment outcome and predictors of response,” PLoS ONE, vol. 10, no. 7, Article ID e0133591, 2015. View at Publisher · View at Google Scholar · View at Scopus